000170609 001__ 170609
000170609 005__ 20240917145501.0
000170609 0247_ $$2doi$$a10.1002/1878-0261.13078
000170609 0247_ $$2pmid$$apmid:34515408
000170609 0247_ $$2ISSN$$a1574-7891
000170609 0247_ $$2ISSN$$a1878-0261
000170609 0247_ $$2altmetric$$aaltmetric:113375896
000170609 037__ $$aDKFZ-2021-02043
000170609 041__ $$aEnglish
000170609 082__ $$a610
000170609 1001_ $$aRingborg, Ulrik$$b0
000170609 245__ $$aThe Porto European Cancer Research Summit 2021.
000170609 260__ $$aHoboken, NJ$$bJohn Wiley & Sons, Inc.$$c2021
000170609 3367_ $$2DRIVER$$aarticle
000170609 3367_ $$2DataCite$$aOutput Types/Journal article
000170609 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726577654_13460
000170609 3367_ $$2BibTeX$$aARTICLE
000170609 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170609 3367_ $$00$$2EndNote$$aJournal Article
000170609 500__ $$a2021 Oct;15(10):2507-2543
000170609 520__ $$aKey stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures - namely translational research, clinical/prevention trials and outcomes research - were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.
000170609 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000170609 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170609 650_7 $$2Other$$aCancer Mission
000170609 650_7 $$2Other$$acancer research/care/prevention continuum
000170609 650_7 $$2Other$$aclinical/prevention trials
000170609 650_7 $$2Other$$acomprehensive cancer centres
000170609 650_7 $$2Other$$ainfrastructures for translational cancer research
000170609 650_7 $$2Other$$aoutcomes research
000170609 650_7 $$2Other$$ascience policy
000170609 7001_ $$aBerns, Anton$$b1
000170609 7001_ $$aCelis, Julio E$$b2
000170609 7001_ $$aHeitor, Manuel$$b3
000170609 7001_ $$aTabernero, Josep$$b4
000170609 7001_ $$00000-0001-9687-2134$$aSchüz, Joachim$$b5
000170609 7001_ $$0P:(DE-He78)933f7d725ac87378f459623783585a1f$$aBaumann, Michael$$b6
000170609 7001_ $$00000-0003-3171-4666$$aHenrique, Rui$$b7
000170609 7001_ $$aAapro, Matti$$b8
000170609 7001_ $$aBasu, Partha$$b9
000170609 7001_ $$aBeets-Tan, Regina$$b10
000170609 7001_ $$aBesse, Benjamin$$b11
000170609 7001_ $$aCardoso, Fátima$$b12
000170609 7001_ $$aCarneiro, Fátima$$b13
000170609 7001_ $$avan den Eede, Guy$$b14
000170609 7001_ $$aEggermont, Alexander$$b15
000170609 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b16$$udkfz
000170609 7001_ $$aGalbraith, Susan$$b17
000170609 7001_ $$aGarralda, Elena$$b18
000170609 7001_ $$aHanahan, Douglas$$b19
000170609 7001_ $$aHofmarcher, Thomas$$b20
000170609 7001_ $$aJönsson, Bengt$$b21
000170609 7001_ $$aKallioniemi, Olli$$b22
000170609 7001_ $$aKásler, Miklós$$b23
000170609 7001_ $$aKondorosi, Eva$$b24
000170609 7001_ $$aKorbel, Jan$$b25
000170609 7001_ $$aLacombe, Denis$$b26
000170609 7001_ $$aCarlos Machado, José$$b27
000170609 7001_ $$00000-0002-8648-5541$$aMartin-Moreno, José M$$b28
000170609 7001_ $$aMeunier, Francoise$$b29
000170609 7001_ $$aNagy, Péter$$b30
000170609 7001_ $$aNuciforo, Paolo$$b31
000170609 7001_ $$00000-0002-1139-2578$$aOberst, Simon$$b32
000170609 7001_ $$aOliveiera, Júlio$$b33
000170609 7001_ $$aPapatriantafyllou, Maria$$b34
000170609 7001_ $$aRicciardi, Walter$$b35
000170609 7001_ $$aRoediger, Alexander$$b36
000170609 7001_ $$aRyll, Bettina$$b37
000170609 7001_ $$aSchilsky, Richard$$b38
000170609 7001_ $$aScocca, Grazia$$b39
000170609 7001_ $$aSeruca, Raquel$$b40
000170609 7001_ $$aSoares, Marta$$b41
000170609 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b42
000170609 7001_ $$aValentini, Vincenzo$$b43
000170609 7001_ $$aVoest, Emile$$b44
000170609 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b45
000170609 7001_ $$aWilking, Nils$$b46
000170609 7001_ $$aWren, Amanda$$b47
000170609 7001_ $$aZitvogel, Laurence$$b48
000170609 773__ $$0PERI:(DE-600)2322586-5$$a10.1002/1878-0261.13078$$gp. 1878-0261.13078$$n10$$p2507-2543$$tMolecular oncology$$v15$$x1878-0261$$y2021
000170609 909CO $$ooai:inrepo02.dkfz.de:170609$$pVDB
000170609 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)933f7d725ac87378f459623783585a1f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000170609 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000170609 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b42$$kDKFZ
000170609 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000170609 9141_ $$y2021
000170609 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-01-28
000170609 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL ONCOL : 2019$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL ONCOL : 2019$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000170609 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000170609 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000170609 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x1
000170609 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x2
000170609 980__ $$ajournal
000170609 980__ $$aVDB
000170609 980__ $$aI:(DE-He78)E220-20160331
000170609 980__ $$aI:(DE-He78)C110-20160331
000170609 980__ $$aI:(DE-He78)B340-20160331
000170609 980__ $$aUNRESTRICTED